Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)

Brepocitinib delivered strong Phase 3 results in non-infectious uveitis, outperforming placebo.

What the company is saying

Roivant and Priovant Therapeutics are highlighting brepocitinib’s statistically significant efficacy in the Phase 3 CLARITY program for non-infectious uveitis (NIU), emphasizing achievement of all primary and key secondary endpoints. The announcement repeatedly stresses the magnitude and breadth of benefit, including sustained steroid-free quiescence, resolution of macular edema, and improved patient-reported visual functioning, even under a more aggressive steroid taper than in prior NIU trials. The company frames these results as a potential turning point for the field, with executive commentary from Quan Dong Nguyen, a leading academic and society president, and Ben Zimmer, Priovant’s CEO, both underscoring the clinical significance and commercial potential. The narrative positions NIU as the next pillar of Priovant’s rare disease immunology franchise, following the commercial launch of LISRAYA for dermatomyositis. Safety is presented as consistent with prior data, with only 3% discontinuation due to adverse events and no new safety signals. The company discloses its intent to file a supplemental New Drug Application (sNDA) for NIU in the first half of 2027, and references ongoing development in other indications.

What the data suggests

The CLARITY program enrolled 371 patients across two studies, randomizing them 1:1 to brepocitinib 45 mg or placebo for 48 weeks, with all patients undergoing a strict 8-week oral corticosteroid regimen and taper. In CLARITY-1, brepocitinib reduced the hazard of treatment failure versus placebo with a hazard ratio of 0.27 (95% CI: 0.17–0.43). Sustained steroid-free quiescence at Week 48 was achieved by 39.4% of brepocitinib patients versus 8.6% for placebo (Δ 31.3%) in CLARITY-1, and 54.9% versus 7.2% (Δ 49.8%) in CLARITY-2. Resolution of macular edema at Week 48 among affected eyes was 40.4% for brepocitinib and 2.1% for placebo (Δ 33.3%) in CLARITY-1, and 42.6% versus 7.0% (Δ 40.1%) in CLARITY-2. For patient-reported visual functioning, ≥5-point improvement in NEI VFQ-25 was seen in 36.4% of brepocitinib patients versus 13.7% for placebo (Δ 21.9%) in CLARITY-1, and 40.4% versus 14.1% (Δ 24.5%) in CLARITY-2. Only 3% discontinued due to adverse events, with most events mild or moderate and no new safety signals. The data are robust, with strong statistical significance across endpoints and clinically meaningful effect sizes. The affected patient population in the US is estimated at 70,000 to 190,000 adults. No financial metrics or commercial projections are disclosed.

Analysis

The announcement is highly positive in tone, but the language is proportionate to the strong, detailed Phase 3 clinical results disclosed. The majority of claims are realised and supported by robust numerical data, including primary and secondary endpoint achievement, hazard ratios, and safety outcomes. Only a small fraction of the announcement is forward-looking, specifically the intent to file an sNDA in the first half of 2027, which is a standard next step after successful Phase 3 results. There is no evidence of exaggerated claims about commercialisation, market size, or financial impact, and no large capital outlay or immediate earnings impact is discussed. The only minor overstatement is in subgroup benefit claims and the comparison to precedent trials, which lack supporting data but do not materially inflate the overall signal. The absence of financial metrics is not a deficiency for a late-stage biotech clinical update.

Risk flags

• ●Regulatory approval risk remains, as brepocitinib is not yet approved for NIU and the sNDA is not planned until the first half of 2027; FDA review could identify issues not seen in the trial or require additional data.
• ●Commercial uptake risk exists even if approved, as the NIU patient population is estimated at 70,000 to 190,000 adults in the United States, and market penetration will depend on payer coverage, physician adoption, and competition.
• ●Longer-term safety risk is possible, as the trials report no new safety signals and only 3% discontinuation due to adverse events, but real-world use could reveal rare or cumulative adverse effects not seen in the 48-week study.
• ●Execution risk is present for Priovant and Roivant in scaling commercial operations for NIU, especially as LISRAYA is their only currently marketed product and the company is building a rare disease franchise from a limited base.

Bottom line

Brepocitinib’s Phase 3 CLARITY results in non-infectious uveitis are both statistically and clinically compelling, with large, consistent effect sizes across all primary and key secondary endpoints and a favorable safety profile. The company’s messaging is confident and data-driven, with credible academic and executive voices lending weight to the narrative. However, the path to commercial value depends on successful sNDA submission and FDA approval, targeted for the first half of 2027, and subsequent market adoption in a rare disease population. No financial or revenue projections are provided, so the immediate investment case rests on clinical momentum rather than near-term earnings. Investors should focus on regulatory progress and any future disclosures about commercial strategy, pricing, and payer engagement. The most important takeaway is that brepocitinib now has strong late-stage data in NIU, but value realization is contingent on regulatory and commercial execution over the next 12–24 months.

Announcement summary

(NASDAQ:ROIV) Roivant and Priovant Therapeutics announced positive results from the Phase 3 CLARITY program evaluating brepocitinib in non-infectious uveitis (NIU). Brepocitinib met the primary endpoint in both the CLARITY-1 and CLARITY-2 studies, demonstrating statistically significant and clinically meaningful benefit on all key secondary endpoints, including sustained steroid-free quiescence at Week 48, chorioretinal vascular leakage, resolution of macular edema, and patient-reported visual functioning. The CLARITY program enrolled 371 patients across two identical studies, with patients randomized 1:1 to once-daily brepocitinib 45 mg or placebo for a 48-week double-masked treatment period. All patients received an 8-week oral corticosteroid regimen of 60 mg/day for 2 weeks followed by a mandatory 6-week steroid taper to zero. The primary endpoint was time to treatment failure, assessed from Week 6 through Week 48. In CLARITY-1, the hazard ratio for treatment failure versus placebo was 0.27 (95% CI: 0.17–0.43). In CLARITY-1, 39.4% of brepocitinib patients achieved sustained steroid-free quiescence at Week 48 compared to 8.6% for placebo (Δ 31.3%; P<0.0001), and in CLARITY-2, 54.9% for brepocitinib versus 7.2% for placebo (Δ 49.8%; P<0.0001). Resolution of macular edema at Week 48 among eyes with macular edema at baseline was 40.4% for brepocitinib and 2.1% for placebo in CLARITY-1 (Δ 33.3%; P=0.0041), and 42.6% for brepocitinib and 7.0% for placebo in CLARITY-2 (Δ 40.1%; P=0.0002). Achievement of ≥5-point improvement in NEI VFQ-25 overall composite score from baseline at Week 48, among subjects with baseline ≤95, was 36.4% for brepocitinib and 13.7% for placebo in CLARITY-1 (Δ 21.9%; P=0.0013), and 40.4% for brepocitinib and 14.1% for placebo in CLARITY-2 (Δ 24.5%; P=0.0003). Brepocitinib was generally well tolerated, with most adverse events mild or moderate, and only 3% of participants discontinuing due to an adverse event. The safety profile was consistent with known data and no new safety signals were observed. NIU is estimated to affect 70,000 to 190,000 adults in the United States. Priovant intends to file a supplemental New Drug Application (sNDA) for brepocitinib for treatment of NIU in the first half of calendar year 2027. Roivant will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, October 21, 2026, to discuss the Phase 3 results, and will also host an investor day on Wednesday, December 9, 2026. Brepocitinib is also under evaluation in a Phase 3 program in cutaneous sarcoidosis and a Phase 2b/3 program in lichen planopilaris. LISRAYA (brepocitinib) is commercially available for adults with dermatomyositis.

Disagree with this article?